Form 8-K - Current report:
SEC Accession No. 0001493152-24-009063
Filing Date
2024-03-06
Accepted
2024-03-06 17:14:53
Documents
15
Period of Report
2024-02-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45124
2 ex2-1.htm EX-2.1 25538
  Complete submission text file 0001493152-24-009063.txt   249370

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evfm-20240229.xsd EX-101.SCH 3009
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evfm-20240229_lab.xml EX-101.LAB 34240
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evfm-20240229_pre.xml EX-101.PRE 22355
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3521
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 24727002
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)